MYCN and prostate adenocarcinoma: Using tissue sourced from benign prostate, prostate adenocarcinoma, and NEPC, a significant overexpression and gene amplification of the protooncogenes MYCN and its stabilising cofactor Aurora kinase A (AURKA) were discovered in 40% of NEPC and 5% of prostate adenocarcinomas [70].